Trump Issues 60-Day Ultimatum to Big Pharma: Cut Drug Prices or Face Crackdown
WASHINGTON — In a bold move targeting rising prescription costs, former President Donald Trump’s administration has issued a 60-day ultimatum to major pharmaceutical companies: lower drug prices for Americans or face sweeping federal action.
According to White House officials, letters were sent to top pharmaceutical CEOs demanding “Most-Favored-Nation” pricing, a policy ensuring that U.S. patients pay no more for medication than consumers in other wealthy nations. The proposal marks one of Trump’s most aggressive efforts yet to tackle drug affordability — an issue that has left millions of Americans struggling or rationing their prescriptions.
Drugmakers have responded with concern, warning that significant price cuts could hinder medical innovation and disrupt research funding. However, critics argue that the industry has long used that defense to protect excessive profit margins while U.S. consumers continue to face some of the highest drug prices in the world.
The standoff sets the stage for a high-stakes battle between the Trump administration and Big Pharma, one that could dramatically reshape both healthcare economics and the future of prescription drug regulation in the United States.
